Q3 FY2026 · ended Aug 31, 2026 · Revenue $673.06M, +8426.3% YoY · Filed Oct 13, 2026
Nurix Therapeutics, Inc. (NRIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Aug 31, 2026, it reported revenue of $673.1 million and net income of $549.8 million. Free cash flow was $614.2 million. As of Aug 31, 2026 it held $720.2 million in cash and investments and $65.3 million in total debt.
Revenue
$673.06M
+8426.3% vs year-ago quarter
Net income
$549.81M
+736.2% vs year-ago quarter
Operating cash flow
$615.63M
+1172.8% vs year-ago quarter
Free cash flow
$614.24M
+1122.1% vs year-ago quarter
EPS
$4.73
+559.2% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
109.25M
+42.1% vs year-ago quarter
Net cash
$654.91M
Q3 FY2026
Operating margin
41.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRIX (Nasdaq)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1549595
- Former names
- Nurix, Inc. (until Sep 18, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Aug 31, 2026 |
Q2 FY2026 May 31, 2026 |
Q1 FY2026 Feb 28, 2026 |
Q4 FY2025 Nov 30, 2025 |
Q3 FY2025 Aug 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $673.1M | $9.0M | $6.3M | $13.6M | $7.9M |
| Operating income | $559.5M | -$94.2M | -$92.5M | -$83.1M | -$91.4M |
| Net income | $549.8M | -$89.5M | -$87.2M | -$78.2M | -$86.4M |
| Diluted EPS | $4.73 | -$0.81 | -$0.79 | -$0.82 | -$1.03 |
| Operating cash flow | $615.6M | -$96.6M | -$71.9M | -$67.8M | -$57.4M |
| Free cash flow | $614.2M | -$98.5M | -$73.0M | -$73.0M | -$60.1M |
| Total assets | $1.2B | $535.5M | $636.1M | $688.1M | $522.5M |
| Total liabilities | $227.0M | $132.9M | $155.2M | $149.4M | $150.2M |
| Stockholders' equity | $968.3M | $402.6M | $480.9M | $538.7M | $372.3M |
| Cash and investments | $720.2M | $67.7M | $71.2M | $247.0M | $78.4M |
| Total debt | $65.3M | $58.1M | $58.7M | $55.7M | $56.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Oct 13, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Jul 9, 2026 | May 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 9, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
All 561 Nurix Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.